Unraveling the Complex Landscape of MDR-TB: A Comprehensive Retrospective Study on Treatment History, Demographics, and Drug Resistance Patterns in District Swat

Khalid Jamal; Muhammad Khalid; Abdul Ahad; Azan Hassan; Shah Hassan Khan; Burhanullah; Samid Ur Rehman

doi:10.70749/ijbr.v2i02.196

Authors

Khalid Jamal Department of Pulmonology, Saidu Medical College & Saidu Group of Teaching Hospital, Swat, Pakistan
Muhammad Khalid Department of Pulmonology, Timergara Medical College, KPK, Pakistan
Abdul Ahad Department of Internal Medicine, Saidu Medical College Swat, KPK, Pakistan
Azan Hassan Department of Pharmacology and Therapeutic, Islam Medical and Dental College, Sialkot, Punjab, Pakistan
Shah Hassan Khan Department of Pathology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China
Burhanullah Department of Internal Medicine Saidu Medical College & Saidu Group of Teaching Hospital, Swat, KPK, Pakistan
Samid Ur Rehman Department of Internal Medicine Saidu Medical College & Saidu Group of Teaching Hospital, Swat, KPK, Pakistan

DOI:

https://doi.org/10.70749/ijbr.v2i02.196

Keywords:

Tuberculosis, MDR-TB, XDR-TB, Drug Resistance.

Abstract

Therapy for tuberculosis (TB) involves the application of first-line medicines (FLDs), such as isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), ethambutol (EMB), and streptomycin (SM). Second-line medications (SLDs) are employed if the first-line therapy fails or the bacteria develop resistance to the FLDs. The present research set out to evaluate the drug-resistant tuberculosis prevalence and determine the drug-resistant patterns in District Swat.

Materials and Methods

This was an observational, hospital-based, retrospective research of previously diagnosed cases of all Drug sensitive TB (DS-TB), MDR-TB, and XDR-TB patients provided by the Programmatic Management of Drug-Resistant TB (PMDT) Saidu Group of Teaching Hospital, Swat from January 2015 to December 2019. There were 15,567 isolates of DS-TB and MDR-TB in all from the research. The data was analyzed applying the statistical software SPSS version 25 (SPSS Inc., Chicago, IL, USA) and Microsoft Excel (Microsoft Office Professional Plus 2016).

Results

According to the results, between January 2014 and December 2019, a total of 15,567 patients were registered from 13 District SWAT centers, comprising 15356 (98.64%) new cases and 211 (1.36%) re-treatment cases with known age and sex. The proportion of TB in the male population (51.9%) was higher than in the female population (48.0 %). Overall treatment success rate (TSR) for PBC cases was (3097) 93.9%.

Conclusion

Finding the baseline susceptibility to first- and second-line medications as soon as possible is necessary to prevent developed drug resistance and unfavorable outcomes, according to the investigation's conclusion

References

Abate, D., et al. (2012). "Epidemiology of anti-tuberculosis drug resistance patterns and trends in tuberculosis referral hospital in Addis Ababa, Ethiopia." BMC research notes 5: 1-6.

Abate, D., et al. (2014). "Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment." The International Journal of tuberculosis and lung disease 18(8): 946-951.

Abdella, K., et al. (2015). "Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest Ethiopia." BMC Public Health 15: 1-7.

Abebe, G., et al. (2012). "Relatively low primary drug resistant tuberculosis in southwestern Ethiopia." BMC research notes 5: 1-6.

Ahmad, A. M., et al. (2012). "Risk factors for multidrug-resistant tuberculosis in urban Pakistan: a multicenter case–control study." International journal of mycobacteriology 1(3): 137-142.

Bakuła, Z., et al. (2016). "Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates." Journal of Microbiology, Immunology and Infection 49(3): 439-444.

Basu, R., et al. (2021). "Socio-demographic and clinical profile of drug resistant tuberculosis patients in a tertiary care centre of Kolkata." Indian Journal of Community Health 33(4): 608-614.

Biadglegne, F., et al. (2014). "Multidrug-resistant tuberculosis in Ethiopia: efforts to expand diagnostic services, treatment and care." Antimicrobial Resistance and Infection Control 3: 1-10.

Brhane, M., et al. (2017). "Molecular detection of multidrug-resistant tuberculosis among smear-positive pulmonary tuberculosis patients in Jigjiga town, Ethiopia." Infection and drug resistance: 75-83.

Chen, Y., et al. (2016). "Resistance to second-line antituberculosis drugs and delay in drug susceptibility testing among multidrug-resistant tuberculosis patients in Shanghai." BioMed Research International 2016.

Chuchottaworn, C., et al. (2015). "Risk factors for multidrug-resistant tuberculosis among patients with pulmonary tuberculosis at the central chest institute of Thailand." PloS one 10(10): e0139986.

Coker, R., et al. (2006). "Risk factors for pulmonary tuberculosis in Russia: case-control study." Bmj 332(7533): 85-87.

Dholakia, Y. N. and D. P. Shah (2013). "Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program." Lung India 30(4): 316-320.

Elmi, O. S., et al. (2016). "Treatment outcomes of patients with multidrug-resistant tuberculosis (MDR-TB) compared with non-MDR-TB infections in peninsular Malaysia." The Malaysian journal of medical sciences: MJMS 23(4): 17.

Espinal, M. A., et al. (2001). "Global trends in resistance to antituberculosis drugs." New England Journal of Medicine 344(17): 1294-1303.

Faustini, A., et al. (2006). "Risk factors for multidrug resistant tuberculosis in Europe: a systematic review." Thorax 61(2): 158-163.

Flora, M., et al. (2013). "Risk factors of multi-drug-resistant tuberculosis in Bangladeshi population: a case control study." Bangladesh Medical Research Council Bulletin 39(1): 34-41.

Gao, J., et al. (2016). "Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis." BMC pulmonary medicine 16: 1-9.

Gebeyehu, M., et al. (2001). "Prevalence of drug resistant tuberculosis in Arsi Zone, Ethiopia." The Ethiopian Journal of Health Development 15(1).

Heep, M., et al. (2001). "Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates." Journal of clinical microbiology 39(1): 107-110.

Hillemann, D., et al. (2005). "Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates." Journal of clinical microbiology 43(8): 3699-3703.

Hoza, A. S., et al. (2015). "Anti-TB drug resistance in Tanga, Tanzania: A cross sectional facility-base prevalence among pulmonary TB patients." Asian Pacific journal of tropical medicine 8(11): 907-913.

Irfan, S., et al. (2006). "Assessment of resistance in multi drug resistant tuberculosis patients." Journal of Pakistan Medical Association 56(9): 397.

Khurram, M., et al. (2012). "Multidrug-resistant tuberculosis in Rawalpindi, Pakistan." The Journal of Infection in Developing Countries 6(01): 29-32.

Kuhn, J. E. (2013). "Current concepts: Rotator cuff pathology in athletes—A source of pain or adaptive pathology?" Current Sports Medicine Reports 12(5): 311-315.

Liu, Q., et al. (2013). "Rates and risk factors for drug resistance tuberculosis in Northeastern China." BMC Public Health 13: 1-7.

Lukoye, D., et al. (2013). "Anti-tuberculosis drug resistance among new and previously treated sputum smear-positive tuberculosis patients in Uganda: results of the first national survey." PloS one 8(8): e70763.

Lv, X.-T., et al. (2017). "Prevalence and risk factors of multi-drug resistant tuberculosis in Dalian, China." Journal of International Medical Research 45(6): 1779-1786.

Masjedi, M. R., et al. (2006). "Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran." Clinical infectious diseases 43(7): 841-847.

Mesfin, Y. M., et al. (2014). "Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis." PloS one 9(1): e82235.

Mulisa, G., et al. (2015). "Multidrug-resistant Mycobacterium tuberculosis and associated risk factors in Oromia Region of Ethiopia." International Journal of Infectious Diseases 39: 57-61.

Mulu, W., et al. (2015). "Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State." African health sciences 15(2): 368-377.

Nguyen, H. B., et al. (2016). "Prevalence of resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients in Viet Nam, 2011." Western Pacific surveillance and response journal: WPSAR 7(2): 35.

NTP (2019) NATIONAL TB CONTROL PROGRAM PAKISTAN ANNUAL REPORT

Otu, A., et al. (2013). "Drug resistance among pulmonary tuberculosis patients in Calabar, Nigeria." Pulmonary medicine 2013.

Paramasivan, C., et al. (2010). "First-and second-line drug resistance patterns among previously treated tuberculosis patients in India." The International Journal of tuberculosis and lung disease 14(2): 243-246.

Porwal, C., et al. (2013). "Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region." PloS one 8(2): e55299.

Rahman, M. A., et al. (2005). "Multi-drug resistant tuberculosis: experience in Bogra." TAJ: Journal of Teachers Association 18(1): 30-36.

Ramachandran, R., et al. (2009). "Surveillance of drug-resistant tuberculosis in the state of Gujarat, India." The International Journal of tuberculosis and lung disease 13(9): 1154-1160.

Rieder, H. L. (2002). Interventions for tuberculosis control and elimination, International Union Against Tuberculosis and Lung Disease Paris.

Seyoum, B., et al. (2014). "Prevalence and drug resistance patterns of Mycobacterium tuberculosis among new smear positive pulmonary tuberculosis patients in eastern Ethiopia." Tuberculosis research and treatment 2014.

Singh, M., et al. (2005). "Prevalence and risk factors for transmission of infection among children in household contact with adults having pulmonary tuberculosis." Archives of disease in childhood 90(6): 624-628.

Smith, S. E., et al. (2015). "Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005–2010." Emerging Infectious Diseases 21(6): 1002.

Steingart, K. R., et al. (2006). "Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review." The Lancet infectious diseases 6(9): 570-581.

Vidyaraj, C., et al. (2017). "Prevalence of rifampicin-resistant Mycobacterium tuberculosis among human-immunodeficiency-virus-seropositive patients and their treatment outcomes." Journal of Epidemiology and Global Health 7(4): 289-294.

Vohra, S. and H. S. Dhaliwal (2020). "Miliary tuberculosis."

WHO (2018) WHO treatment guidelines for rifampicin- and multidrug-resistant tuberculosis, 2018 update.

WHO (2019) Global tuberculosis report.

Workicho, A., et al. (2017). "Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: a case-control study." Infection and drug resistance: 91-96.

Yang, Y. R., et al. (2012). "Evaluation of the tuberculosis programme in Ningxia Hui Autonomous region, the People’s Republic of China: a retrospective case study." BMC Public Health 12: 1-8.

Yimer, S. A., et al. (2012). "Primary drug resistance to anti‐tuberculosis drugs in major towns of Amhara region, Ethiopia." Apmis 120(6): 503-509.